258 related articles for article (PubMed ID: 23056173)
21. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor.
Pineda Torra I; Claudel T; Duval C; Kosykh V; Fruchart JC; Staels B
Mol Endocrinol; 2003 Feb; 17(2):259-72. PubMed ID: 12554753
[TBL] [Abstract][Full Text] [Related]
22. Transcriptional Regulation of Human UDP-Glucuronosyltransferase 2B10 by Farnesoid X Receptor in Human Hepatoma HepG2 Cells.
Lu D; Wang S; Xie Q; Guo L; Wu B
Mol Pharm; 2017 Sep; 14(9):2899-2907. PubMed ID: 28267333
[TBL] [Abstract][Full Text] [Related]
23. Farnesoid X receptor, through the binding with steroidogenic factor 1-responsive element, inhibits aromatase expression in tumor Leydig cells.
Catalano S; Malivindi R; Giordano C; Gu G; Panza S; Bonofiglio D; Lanzino M; Sisci D; Panno ML; Andò S
J Biol Chem; 2010 Feb; 285(8):5581-93. PubMed ID: 20026603
[TBL] [Abstract][Full Text] [Related]
24. Tumor suppressor NDRG2 inhibits glycolysis and glutaminolysis in colorectal cancer cells by repressing c-Myc expression.
Xu X; Li J; Sun X; Guo Y; Chu D; Wei L; Li X; Yang G; Liu X; Yao L; Zhang J; Shen L
Oncotarget; 2015 Sep; 6(28):26161-76. PubMed ID: 26317652
[TBL] [Abstract][Full Text] [Related]
25. Chronic activation of FXR-induced liver growth with tissue-specific targeting Cyclin D1.
Wu W; Wu Q; Liu X
Cell Cycle; 2019 Aug; 18(15):1784-1797. PubMed ID: 31223053
[TBL] [Abstract][Full Text] [Related]
26. Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro.
Gao X; Fu T; Wang C; Ning C; Liu K; Liu Z; Sun H; Ma X; Huo X; Yang X; Zou M; Meng Q
Toxicol Appl Pharmacol; 2018 Jun; 348():105-116. PubMed ID: 29660435
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of N-Myc downstream-regulated gene 2 (NDRG2) regulates the proliferation and invasion of bladder cancer cells in vitro and in vivo.
Li R; Yu C; Jiang F; Gao L; Li J; Wang Y; Beckwith N; Yao L; Zhang J; Wu G
PLoS One; 2013; 8(10):e76689. PubMed ID: 24146910
[TBL] [Abstract][Full Text] [Related]
28. Hyperthermia-induced NDRG2 upregulation inhibits the invasion of human hepatocellular carcinoma via suppressing ERK1/2 signaling pathway.
Guo Y; Ma J; Wu L; Wang Q; Li X; Li X; Zhang Y; Zhang J; Yao L; Zhang J; Liu W
PLoS One; 2013; 8(4):e61079. PubMed ID: 23630579
[TBL] [Abstract][Full Text] [Related]
29. Bile salt export pump is dysregulated with altered farnesoid X receptor isoform expression in patients with hepatocellular carcinoma.
Chen Y; Song X; Valanejad L; Vasilenko A; More V; Qiu X; Chen W; Lai Y; Slitt A; Stoner M; Yan B; Deng R
Hepatology; 2013 Apr; 57(4):1530-41. PubMed ID: 23213087
[TBL] [Abstract][Full Text] [Related]
30. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression.
Claudel T; Inoue Y; Barbier O; Duran-Sandoval D; Kosykh V; Fruchart J; Fruchart JC; Gonzalez FJ; Staels B
Gastroenterology; 2003 Aug; 125(2):544-55. PubMed ID: 12891557
[TBL] [Abstract][Full Text] [Related]
31. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY
Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525
[TBL] [Abstract][Full Text] [Related]
32. Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation.
Degirolamo C; Modica S; Vacca M; Di Tullio G; Morgano A; D'Orazio A; Kannisto K; Parini P; Moschetta A
Hepatology; 2015 Jan; 61(1):161-70. PubMed ID: 24954587
[TBL] [Abstract][Full Text] [Related]
33. Activation of the nuclear receptor FXR enhances hepatocyte chemoprotection and liver tumor chemoresistance against genotoxic compounds.
Vaquero J; Briz O; Herraez E; Muntané J; Marin JJ
Biochim Biophys Acta; 2013 Oct; 1833(10):2212-9. PubMed ID: 23680185
[TBL] [Abstract][Full Text] [Related]
34. Impact of bile acids on the growth of human cholangiocarcinoma via FXR.
Dai J; Wang H; Shi Y; Dong Y; Zhang Y; Wang J
J Hematol Oncol; 2011 Oct; 4():41. PubMed ID: 21988803
[TBL] [Abstract][Full Text] [Related]
35. NDRG2 inhibits hepatocellular carcinoma adhesion, migration and invasion by regulating CD24 expression.
Zheng J; Li Y; Yang J; Liu Q; Shi M; Zhang R; Shi H; Ren Q; Ma J; Guo H; Tao Y; Xue Y; Jiang N; Yao L; Liu W
BMC Cancer; 2011 Jun; 11():251:1-9. PubMed ID: 21676268
[TBL] [Abstract][Full Text] [Related]
36. FXR Acts as a Metastasis Suppressor in Intrahepatic Cholangiocarcinoma by Inhibiting IL-6-Induced Epithelial-Mesenchymal Transition.
Lv B; Ma L; Tang W; Huang P; Yang B; Wang L; Chen S; Gao Q; Zhang S; Xia J
Cell Physiol Biochem; 2018; 48(1):158-172. PubMed ID: 30001540
[TBL] [Abstract][Full Text] [Related]
37. Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition.
Vaquero J; Monte MJ; Dominguez M; Muntané J; Marin JJ
Biochem Pharmacol; 2013 Oct; 86(7):926-39. PubMed ID: 23928191
[TBL] [Abstract][Full Text] [Related]
38. Hematopoietically expressed homeobox is a target gene of farnesoid X receptor in chenodeoxycholic acid-induced liver hypertrophy.
Xing X; Burgermeister E; Geisler F; Einwächter H; Fan L; Hiber M; Rauser S; Walch A; Röcken C; Ebeling M; Wright MB; Schmid RM; Ebert MP
Hepatology; 2009 Mar; 49(3):979-88. PubMed ID: 19072826
[TBL] [Abstract][Full Text] [Related]
39. Bile acid receptor agonist GW4064 regulates PPARγ coactivator-1α expression through estrogen receptor-related receptor α.
Dwivedi SK; Singh N; Kumari R; Mishra JS; Tripathi S; Banerjee P; Shah P; Kukshal V; Tyagi AM; Gaikwad AN; Chaturvedi RK; Mishra DP; Trivedi AK; Sanyal S; Chattopadhyay N; Ramachandran R; Siddiqi MI; Bandyopadhyay A; Arora A; Lundåsen T; Anakk SP; Moore DD; Sanyal S
Mol Endocrinol; 2011 Jun; 25(6):922-32. PubMed ID: 21493670
[TBL] [Abstract][Full Text] [Related]
40. Combined aberrant expression of N-Myc downstream-regulated gene 2 and CD24 is associated with disease-free survival and overall survival in patients with hepatocellular carcinoma.
Li B; Shao Q; Ji D; Li F; Guo X; Chen G
Diagn Pathol; 2014 Oct; 9():209. PubMed ID: 25338637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
